Micro-Tech (Nanjing) Co., Ltd. (stock ticker symbol: MTM; code: 688029) is mainly engaged in the R&D, manufacturing and sales of minimally invasive medical devices. In line with our mission of "supporting clinicians with technology and innovation", MTM is committed to providing high-quality products and services to hospitals and clinics around the world, advancing the quality of care, improving patient outcome and maintaining low costs.
After 20 years of innovation-driven development, MTM has extended its product family from non-vascular stents to three major product platforms, namely, endoscopic diagnostic instruments and consumables, tumor ablation instruments and consumables, and endoscopic optical coherence tomography (EOCT). Further, MTM has expanded our market presence from China to about 90 other countries around the world. MTM has become a leading company in the field of minimally invasive medical technology through scientific research and innovation, competitive advantage in core products and rapid growth in market share.
MTM has a stable, high-caliber, international and interdisciplinary technical team with expertise in biomedical engineering, chemical engineering, mechanical engineering, automation and computer sciences, providing a strong foundation for the company's constant innovation. MTM has won three national awards including runner-up for theNational Prize for Progress in Science and Technology, and 13 provincial and ministerial awards. Further, MTM has 47 domestic and foreign invention patents, 73 domestic Class II and Class III registration certificates, 37 U.S. FDA cleared devices, and 40 European CE certificates.
As of the end of 2020, MTM achieved an operating income of RMB1326 million and a net profit of RMB 260 million.
|Earnings Per Share||1.9556||2.6657||1.9270|
|R&D expenditure as a % of operating revenue||7.51%||5.38%||5.33%|
|Total Owners' Equity||2,663.63||2,528.10||620.37|
|Net Cash Flows-Operating||231.27||252.49||192.32|
|Net Cash Flows-Investing||-163.10||-1,390.16||-26.30|
|Net Cash Flows-Financing||-51.68||1,469.84||-4.72|
|Name||No. of Shares Held (mn)||% of Shares Held|
|Nanjing New weichuang Management Consulting Co., Ltd.||30.76||23.07%|
|Shenzhen Zhongke Merchants Venture Investment Co., Ltd.||30.18||22.63%|
|Shenzhen Huasheng Lingfeng Equity Investment（Limited Partnership）||4.50||3.37%|
|Green Paper Investment Limited||3.77||2.82%|
|Bank of China Limited - E Fund Healthcare Hybrid Securities Investment Fund||1.90||1.43%|
|Nanjing Maitai Investment Co., Ltd||1.75||1.32%|
|China Merchants Bank Co., Ltd. - Huaxia SSE Innovation Board 50 component ETF Securities Investment Fund||1.04||0.78%|
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.